A Phase 2 Randomized, Placebo-controlled Crossover Trial to Evaluate Safety and Efficacy of Platelet-rich Plasma Injections for Peyronie's Disease: Clinical Trial Update

Kevin Y Chu; Manuel L Molina; Brian Ledesma; Isaac Zucker; Russell G Saltzman; Thomas A Masterson; Ranjith Ramasamy

doi:10.1016/j.euf.2022.08.017

A Phase 2 Randomized, Placebo-controlled Crossover Trial to Evaluate Safety and Efficacy of Platelet-rich Plasma Injections for Peyronie's Disease: Clinical Trial Update

Eur Urol Focus. 2023 Jan;9(1):11-13. doi: 10.1016/j.euf.2022.08.017. Epub 2022 Sep 10.

Authors

Kevin Y Chu¹, Manuel L Molina¹, Brian Ledesma¹, Isaac Zucker¹, Russell G Saltzman², Thomas A Masterson¹, Ranjith Ramasamy³

Affiliations

¹ Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
² Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
³ Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA. Electronic address: ramasamy@miami.edu.

PMID: 36100520
DOI: 10.1016/j.euf.2022.08.017

Abstract

Intralesional injection of platelet-rich plasma for Peyronie's disease appears to be safe according to early observations from an ongoing clinical trial. Efficacy data remain elusive until completion of the trial.

Trial registration: ClinicalTrials.gov NCT04512287.

Publication types

Randomized Controlled Trial
Clinical Trial, Phase II
Research Support, Non-U.S. Gov't

MeSH terms

Cross-Over Studies
Humans
Injections, Intralesional
Male
Penile Induration* / therapy

Associated data

ClinicalTrials.gov/NCT04512287